- Business
- Shandong Keyuan Pharmaceutical Co., Ltd. is a China-based pharmaceutical company that researches, develops, manufactures, and markets active pharmaceutical ingredients (APIs), chemical intermediates, and finished dosage formulations. The company operates across multiple therapeutic categories, offering chemical APIs and intermediate compounds, including anti-diabetic agents such as metformin hydrochloride, gliclazide, and vildagliptin; cardiovascular medications such as isosorbide mononitrate, isosorbide dinitrate, and esmolol hydrochloride; psychiatric and central nervous system treatments such as fluoxetine hydrochloride and lurasidone hydrochloride; anesthetic agents such as ropivacaine hydrochloride and isoflurane; and other chemical intermediates such as clarithromycin lactobionate, xanthinol nicotinate, and amlexanox. Through its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., the company produces and distributes finished chemical preparations across various delivery forms, including oral solid tablets and capsules; oral liquids; injectable solutions; topical liniments, pastes, and drops; and aerosol sprays. Additionally, the company provides international contract manufacturing organization (CMO) and custom synthesis services for global pharmaceutical innovators, alongside an expanding product portfolio encompassing pharmaceutical excipients, cosmetic raw materials, and functional health additives under its integrated API-plus business model. Founded in 2004 and headquartered in Jinan, Shandong Province, China, Shandong Keyuan Pharmaceutical operates as a core pharmaceutical unit of Linuo Group, serving domestic healthcare institutions and commercial clients while exporting to nearly 200 customers across more than 50 countries and regions throughout Asia, Europe, North America, and South America under regulatory accreditations from the US FDA, EDQM, PMDA, and MFDS. In recent operational and corporate developments, following its public listing on the Shenzhen Stock Exchange ChiNext board in April 2023, the company pursued internal asset consolidation within Linuo Group through a proposed multi-billion-yuan acquisition of traditional Chinese medicine producer Shandong Hongjitang Pharmaceutical Group Co., Ltd., which was initiated in late 2024 and subsequently terminated in late 2025 due to changing capital market conditions; the company has since refocused capital and operational resources on its core chemical API and formulation capabilities, securing recent regulatory approvals for new pipeline products such as rotigotine API while expanding capacity across its specialized chronic disease treatment lines.